Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for the simultaneous determination of five first-line antituberculosis drugs in plasma

Analytical and Bioanalytical Chemistry

Volumn 405, Issue 19, 2013, Pages 6323-6335

  Zhou, Zhifeng ^a   Wu, Xianbo ^a   Wei, Qinzhi ^a   Liu, Yungang ^a   Liu, Peng ^a   Ma, Ande ^a   Zou, Fei ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Antituberculosis drug; Hydrophilic interaction liquid chromatography; Tandem mass spectrometry; Therapeutic drug monitoring

Indexed keywords

ANTITUBERCULOSIS; HYDROPHILIC INTERACTION LIQUID CHROMATOGRAPHIES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LOWER LIMIT OF QUANTIFICATIONS; SIMULTANEOUS DETERMINATIONS; TANDEM MASS SPECTROMETRY; THERAPEUTIC DRUG MONITORING; US FOOD AND DRUG ADMINISTRATION;

ANTIBIOTICS; CHROMATOGRAPHY; HYDRAZINE; PATIENT MONITORING;

MASS SPECTROMETRY;

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHEMICAL PHENOMENA; CHILD; DRUG MONITORING; EQUIPMENT; EVALUATION; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; METHODOLOGY; MIDDLE AGED; TANDEM MASS SPECTROMETRY; TUBERCULOSIS; VALIDATION STUDY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHROMATOGRAPHY, LIQUID; DRUG MONITORING; ETHAMBUTOL; FEMALE; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; ISONIAZID; MALE; MIDDLE AGED; PYRAZINAMIDE; RIFAMPIN; STREPTOMYCIN; TANDEM MASS SPECTROMETRY; TUBERCULOSIS; YOUNG ADULT;

EID: 84880135113     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-013-7049-0     Document Type: Article

References (41)

1. WHO (2012) Global tuberculosis report 2012. Available via http://www.who.int/tb/publications/global-report/en/
2. WHO (2003) Treatment of tuberculosis: guideline for national programmes, 3rd edn. Word Health Organization, Geneva
3. Kayhan S, Akgüneş A (2011) Therapeutic monitoring of isoniazid, rifampicin, ethambutol and pyrazinamide serum levels in the treatment of active pulmonary tuberculosis and determinants of their serum concentrations. Afr J Pharm Pharmacol 5(17):2035-2041
4. Heysell SK, Moore JL, Keller SJ, Houpt ER (2010) Therapeutic drug monitoring for slow response to tuberculosis treatment in a state control program, Virginia, USA. Emerg Infect Dis 16(10):1546-1553
5. Peloquin CA (2002) Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62(15):2169-2183
6. Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R (2012) Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 25(1):83-86
7. Taneja D, Kaur D (1990) Study on hepatotoxicity and other side-effects of antituberculosis drugs. J India Med Assoc 88:278-280
8. Kimerling ME, Phillips P, Patterson P, Hall M, Robinson CA, Dunlap NE (1998) Low serum antimycobacterial drug levels in non-HIV-infected tuberculosis patients. Chest 113(5):1178-1183
9. Tappero J, Bradford W, Agerton T, Hopewell P, Reingold A, Lockman S, Oyewo A, Talbot E, Kenyon T, Moeti T, Moffat H, Peloquin C (2005) Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana. Clin Infect Dis 41:461-469
10. Ray J, Gardiner I, Marriott D (2003) Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 33(5-6):229-234
11. Allanson AL, Cotton MM, Tettey JNA, Boyter AC (2007) Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: a potential method for therapeutic drug monitoring. J Pharm Biomed Anal 44(4):963-969
12. Guermouche S, Guermouche MH (2004) Solid-phase extraction and HPTLC determination of isoniazid and acetylisoniazid in serum. Comparison with HPLC. J Chromatogr Sci 42(5):250-253
13. Breda M, Marrari P, Pianezzola E, Strolin Benedetti M (1996) Determination of ethambutol in human plasma and urine by high-performance liquid chromatography with fluorescence detection. J Chromatogr A 729(1-2):301-307
14. Zhou Z, Chen L, Liu P, Shen M, Zou F (2010) Simultaneous determination of isoniazid, pyrazinamide, rifampicin and acetylisoniazid in human plasma by high-performance liquid chromatography. Anal Sci 26(11):1133-1138
15. Moussa LA, Khassouani CE, Soulaymani R, Jana M, Cassanas G, Alric R, Hüe B (2002) Therapeutic isoniazid monitoring using a simple high-performance liquid chromatographic method with ultraviolet detection. J Chromatogr B 766(1):181-187
16. Khuhawar MY, Rind FMA (2002) Liquid chromatographic determination of isoniazid, pyrazinamide and rifampicin from pharmaceutical preparations and blood. J Chromatogr B 766(2):357-363
17. Sarri AK, Megoulas NC, Koupparis MA (2006) Development of a novel method based on liquid chromatography-evaporative light scattering detection for the direct determination of streptomycin and dihydrostreptomycin in raw materials, pharmaceutical formulations, culture media and plasma. J Chromatogr A 1122(1-2):275-278
18. Khuhawar MY, Zardari LA (2006) Capillary gas chromatographic determination of isoniazid in pharmaceutical preparations and blood by precolumn derivatization with trifluoroacetylacetone. J Food Drug Anal 14(4):323-328
19. Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA (1999) The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol. Am J Respir Crit Care Med 159(5):1580-1584
20. Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT (2009) Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma. J Chromatogr B 877(3):285-290
21. Wang A, Zhang W, Sun J, Liu JF, Sang YS, Gao S, Hee ZG (2007) HPLC-MS analysis of isoniazid in dog plasma. Chromatographia 66:741-745
22. Granados O, Meza G (2007) A direct HPLC method to estimate streptomycin and its putative ototoxic derivative, streptidine, in blood serum: application to streptomycin-treated humans. J Pharm Biomed Anal 43(2):625-630
23. Chen XY, Song B, Jiang HJ, Yu K, Zhong DF (2005) A liquid chromatography/tandem mass spectrometry method for the simultaneous quantification of isoniazid and ethambutol in human plasma. Rapid Commun Mass Spectrom 19(18):2591-2596
24. Gong Z, Basir Y, Chu D, McCort-Tipton M (2009) A rapid and robust liquid chromatography/tandem mass spectrometry method for simultaneous analysis of anti-tuberculosis drugs - ethambutol and pyrazinamide in human plasma. J Chromatogr B 877(16-17):1698-1704
25. Song SH, Jun SH, Park KU, Yoon Y, Lee JH, Kim JQ, Song J (2007) Simultaneous determination of first-line anti-tuberculosis drugs and their major metabolic ratios by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21(7):1331-1338
26. Minikis RM, Dolan JW (2003) Extracolumn effects. LCGC N Am 21(11):1050-1054
27. US Department of Health and Human Services, Food and Drug Administration (2001) Guidance for industry, bioanalytical method validation. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf
28. European Medicines Agency (2011) Guideline on bioanalytical method validation. EMEA/CHMP/EWP/192217/2009. http://www.ema.europa.eu/ema/index.jsp? curl=pages/includes/document/document-detail.jsp?webContentId= WC500109686&murl=menus/document-library/document-library.jsp&mid= WC0b01ac058009a3dc
29. Matuszewski BK, Constanzer ML, Chavez-Eng CM (2003) Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 75(13):3019-3030
30. World Anti-Doping Agency (2010) WADA technical document TD2010IDCR. World Anti-Doping Agency, Montreal
31. Fang PF, Cai HL, Li HD, Zhu RH, Tan QY, Gao W, Xu P, Liu YP, Zhang WY, Chen YC, Zhang F (2010) Simultaneous determination of isoniazid, rifampicin, levofloxacin in mouse tissues and plasma by high performance liquid chromatography-tandem mass spectrometry. J Chromatogr B 878(24):2286-2291
32. Gremilogianni AM, Megoulas NC, Koupparis MA (2010) Hydrophilic interaction vs ion pair liquid chromatography for the determination of streptomycin and dihydrostreptomycin residues in milk based on mass spectrometric detection. J Chromatogr A 1217(43):6646-6651
33. García MC, Hogenboom AC, Zappey H, Irth H (2002) Effect of the mobile phase composition on the separation and detection of intact proteins by reversed-phase liquid chromatography-electrospray mass spectrometry. J Chromatogr A 957(2):187-199
34. Hemström P, Irgum K (2006) Hydrophilic interaction chromatography. J Sep Sci 29(12):1784-1821
35. Jandera P (2011) Stationary and mobile phases in hydrophilic interaction chromatography: a review. Anal Chim Acta 692(1-2):1-25
36. Nguyen HP, Schug KA (2008) The advantages of ESI-MS detection in conjunction with HILIC mode separations: fundamentals and applications. J Sep Sci 31(9):1465-1480
37. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA (2001) Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 21(9):1037-1045
38. Magis-Escurra C, van den Boogaard J, Ijdema D, Boeree M, Aarnoutse R (2012) Therapeutic drug monitoring in the treatment of tuberculosis patients. Pulm Pharmacol Ther 25(1):83-86
39. Fahimi F, Kobarfard F, Tabarsi P, Hemmati S, Salamzadeh J, Baniasadi S (2011) Isoniazid blood levels in patients with pulmonary tuberculosis at a tuberculosis referral center. Chemotherapy 57(1):7-11
40. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE (2009) Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 29(5):503-510
41. Notari S, Mancone C, Sergi M, Gullotta F, Bevilacqua N, Tempestilli M, Urso R, Lauria FN, Pucillo LP, Tripodi M, Ascenzi P (2010) Determination of antituberculosis drug concentration in human plasma by MALDI-TOF/TOF. IUBMB Life 62(5):387-393